Edition:
United States

Bristol-Myers Squibb Co (BMY)

BMY on New York Consolidated

63.49USD
20 Sep 2017
Change (% chg)

$0.56 (+0.89%)
Prev Close
$62.93
Open
$62.92
Day's High
$63.72
Day's Low
$62.72
Volume
5,561,290
Avg. Vol
7,004,454
52-wk High
$63.72
52-wk Low
$46.01

Summary

Name Age Since Current Position

Giovanni Caforio

52 2017 Chairman of the Board, Chief Executive Officer

Charles Bancroft

57 2016 Chief Financial Officer and Executive Vice President - Global Business Operations

Louis Schmukler

61 2011 President - Global Manufacturing and Supply

Ann Judge

51 2016 Chief Human Resource Officer, Senior Vice President

Thomas Lynch

56 2017 Executive Vice President, Chief Scientific Officer

Sandra Leung

56 2015 Executive Vice President, General Counsel

Murdo Gordon

50 2016 Executive Vice President, Chief Commercial Officer

Paul von Autenried

55 2016 Senior Vice President, Chief Information Officer

Anne Nielsen

56 2013 Senior Vice President, Chief Compliance and Ethics Officer

Joseph Caldarella

61 2010 Senior Vice President, Corporate Controller

John Elicker

57 2012 Senior Vice President - Public Affairs

Emmanuel Blin

47 2016 Senior Vice President, Chief Strategy Officer

Peter Arduini

52 2016 Independent Director

Robert Bertolini

55 2017 Independent Director

Matthew Emmens

65 2017 Independent Director

Michael Grobstein

74 2007 Independent Director

Alan Lacy

63 2008 Independent Director

Dinesh Paliwal

59 2013 Independent Director

Theodore Samuels

62 2017 Independent Director

Vicki Sato

68 2006 Independent Director

Gerald Storch

60 2012 Independent Director

Biographies

Name Description

Giovanni Caforio

Dr. Giovanni Caforio M.D., is Chairman of the Board, Chief Executive Officer of the Company., Effective May 02 2017. He has been our Chief Executive Officer since May 2015 and our Chairman-Designate since December 2016. He was our Chief Operating Officer from June 2014 to May 2015, and he served as Executive Vice President and Chief Commercial Officer from November 2013 to June 2014. From October 2011 to November 2013, he served as President, U.S. Dr. Caforio held the position of Senior Vice President, Global Commercialization and Immunology from May 2010 to October 2011. Prior to that, he served as Senior Vice President, Oncology, U.S. and Global Commercialization from March 2009 to May 2010. From January 2007 to March 2009 he served as Senior Vice President, U.S. Oncology and from May 2004 to January 2007, he served as Senior Vice President, European Marketing and Brand Commercialization. Dr. Caforio is a member of the Board of Trustees of Hun School of Princeton and the Pharmaceutical Research and Manufacturers of America.

Charles Bancroft

Mr. Charles A. Bancroft is Chief Financial Officer and Executive Vice President - Global Business Operations of the Company. He has been appointed as Executive Vice President effective October 19, 2011. He joined Bristol-Myers Squibb in 1984 and has since held positions of increasing responsibility within the finance organization, including international assignments, senior leadership positions in the global pharmaceutical business and also with ConvaTec. He received a B.S. in Accounting from Drexel University, his M.B.A. in Finance from Temple University and is a certified public accountant.

Louis Schmukler

Mr. Louis S. Schmukler is President - Global Manufacturing and Supply of the Company. From 2007 to 2009, he was Senior Vice President, Pharmaceutical Operating Unit, Wyeth and from 2009 to 2011 – Senior Vice President, Specialty/Biotechnology Operating Unit, Pfizer.

Ann Judge

Ms. Ann Powell Judge is Chief Human Resource Officer, Senior Vice President of the Company. From 2009 to 2013 – Chief Human Resources Officer, Shire Pharmaceuticals; 2013 to 2016 – Senior Vice President, Global Human Resources; 2016 to present – Senior Vice President, Chief Human Resources Officer.

Thomas Lynch

Dr. Thomas J. Lynch, Jr., M.D., Ph.D., is appointed as Executive Vice President, Chief Scientific Officer of the Company., effective March 16, 2017. He has served as the Chairman and Chief Executive Officer of Massachusetts General Physicians Organization since July 2015. He has also served as a member of the Board of Directors of Massachusetts General Hospital since 2015. From 2009 to 2015, he was the Director of Yale Cancer Center and the Richard and Jonathan Sackler Professor of Internal Medicine, Yale Cancer Center, Yale School of Medicine. He also served as the Physician-in-Chief of Smilow Cancer Hospital, Yale-New Haven. Prior to 2009, he served as Professor of Medicine at Harvard Medical School and Chief of Hematology/Oncology at Massachusetts General Hospital. Dr. Lynch is a member of the American Association for Cancer Research, the American Society of Clinical Oncology, and the International Association for the Study of Lung Cancer.

Sandra Leung

Ms. Sandra Leung is Executive Vice President, General Counsel of the Company. From 2007 to 2014 – General Counsel and Corporate Secretary; 2014 to 2015 – Executive Vice President, General Counsel and Corporate Secretary; 2015 to present – Executive Vice President, General Counsel.

Murdo Gordon

Mr. Murdo Gordon has been appointed as Executive Vice President, Chief Commercial Officer of the Company., effective June 21, 2016. From 2011 to 2013 – Senior Vice President, Oncology and Immunology; 2013 to 2015 – President, U.S. Pharmaceuticals; 2015 to 2016 – Senior Vice President, Head of Worldwide Markets; 2016 to present – Executive Vice President, Chief Commercial Officer.

Paul von Autenried

Mr. Paul von Autenried is Senior Vice President, Chief Information Officer of the company. From 2011 to 2012 – Senior Vice President and Chief Information Officer; 2012 to 2016 – Senior Vice President, Enterprise Services and Chief Information Officer; 2016 to present – Senior Vice President, Chief Information Officer.

Anne Nielsen

Ms. Anne Nielsen is Senior Vice President, Chief Compliance and Ethics Officer of the Company. From 2009 to 2013 – Vice President and Associate General Counsel; 2013 to 2013 – Senior Vice President and Deputy General Counsel; 2013 to present – Senior Vice President and Chief Compliance and Ethics Officer.

Joseph Caldarella

Mr. Joseph C. Caldarella is Senior Vice President, Corporate Controller of the company. From 2005 to 2010, Vice President and Corporate Controller. He was 1998 to 2005 - Vice President, Finance, Pharmaceutical Research Institute, a division of the Company.

John Elicker

Mr. John E. Elicker is Senior Vice President - Public Affairs of the company. From 2000 to 2002 – Senior Director, Investor Relations, 2002 to 2010 –Vice President, Investor Relations, 2010 to 2012 – Senior Vice President, Investor Relations.

Emmanuel Blin

Mr. Emmanuel Blin is Senior Vice President, Chief Strategy Officer of the Company. From 2010 to 2013 – President & General Manager, Japan 2013 to 2015 – President, Global Commercialization 2015 to 2016 – Senior Vice President, Head of Commercialization, Policy and Operations 2016 to present – Senior Vice President, Chief Strategy Officer

Peter Arduini

Mr. Peter J. Arduini has been appointed as Independent Director of the company., effective April 1, 2016. He has been President and Chief Executive Officer of Integra LifeSciences Holdings Corporation, a global medical technology company, since January 2012 and currently serves as a member of Integra's Board of Directors. He served as President and Chief Operating Officer of Integra from November 2010 to January 2012. Before joining Integra, Mr. Arduini was Corporate Vice President and President of Medication Delivery, Baxter Healthcare, from 2005 to 2010. Prior to joining Baxter, he worked for General Electric Healthcare, where he spent much of his 15 years in a variety of management roles for domestic and global businesses, culminating in leading the global functional imaging business. Mr. Arduini also serves on the Board of Directors of ADVAMED (the Advanced Medical Technology Association), the Board of Directors of MDIC (the Medical Device Innovation Consortium), and the Board of Directors of the National Italian American Foundation.

Robert Bertolini

Mr. Robert J. Bertolini , CPA., is Independent Director of the Company. Mr. Bertolini, who served as President and Chief Financial Officer of Bausch & Lomb Incorporated from February 2013 until August 2013 (until its acquisition by Valeant Pharmaceuticals). Previously, Mr. Bertolini served as Executive Vice President and Chief Financial Officer at Schering-Plough Corp. from November 2003 until November 2009 (through its merger with Merck & Co.) with responsibility for tax, accounting and financial asset management. Prior to joining Schering-Plough, Mr. Bertolini spent 20 years at PricewaterhouseCoopers LLP, ultimately leading its global pharmaceutical industry practice. Mr. Bertolini also serves on the Board of Directors of Actelion Pharmaceuticals Ltd.

Matthew Emmens

Mr. Matthew W. Emmens is Independent Director of the Company. Mr. Emmens served as Chief Executive Officer of Shire PLC from 2003 to 2008 and Chairman of the Board from 2008 to 2014. He also served as a Director of Vertex Pharmaceuticals Incorporated from 2004 to 2009, Chairman, President and Chief Executive Officer from 2009 to 2012 and Director from 2012 to 2013. Mr. Emmens served as President, Worldwide Pharmaceuticals of Merck KGaA from 1999 to 2003, as Chief Executive Officer, Commercial Operations of Astra Merck Inc. from 1992 to 1999 and in Sales, Marketing and Administration positions for Merck & Co, Inc. from 1974 to 1991.

Michael Grobstein

Mr. Michael Grobstein is Independent Director of Bristol-Myers Squibb Company. He is a retired Vice Chairman of Ernst & Young LLP, an independent registered public accounting firm. He worked with Ernst & Young from 1964 to 1998, and was admitted as a partner in 1975. Mr. Grobstein served as Vice Chairman-International Operations from 1993 to 1998, as Vice Chairman-Planning, Marketing and Industry Services from 1987 to 1993, and Vice Chairman-Accounting and Auditing Services from 1984 to 1987. He serves on the Board of Trustees and Executive Committee and is the Treasurer of the Central Park Conservancy. He also serves on the Board of Directors of the Peer Health Exchange, Inc.

Alan Lacy

Mr. Alan J. Lacy is Independent Director of Bristol-Myers Squibb Company. He is currently the Non-Executive Chairman of Dave & Buster's Entertainment Inc. and previously served as the Chairman and Chief Executive Officer of Sears, Roebuck and Co. and the Vice Chairman and Chief Executive Officer of its successor, Sears Holdings Corporation, from 2000 to 2005. Mr. Lacy also served as Vice Chairman of Sears Holdings Corporation from 2005 to 2006. More recently, Mr. Lacy served as Senior Advisor to Oak Hill Capital Partners, L.P., a private equity investment firm, from 2007 to 2014. He is a Trustee of Fidelity Funds and the California Chapter of The Nature Conservancy. Mr. Lacy is a Director of the Center for Advanced Study in the Behavioral Sciences at Stanford University.

Dinesh Paliwal

Mr. Dinesh C. Paliwal Independent Director of Bristol-Myers Squibb Company. He served as Chairman, President and Chief Executive Officer of Harman International Industries, Inc., the connected technologies company for automotive, consumer and enterprise markets, from July 2008 to March 2017 (until its acquisition by Samsung Electronics Co., Ltd.). Following the merger with Samsung Electronics, he continues to serve as Chief Executive Officer and Director of the standalone Harman subsidiary. He has served as President and Chief Executive Officer of Harman since July 2007. Prior to joining Harman, Mr. Paliwal served as a member of the Group Executive Committee of ABB Ltd., a provider of industrial automation, power transmission systems and services, from January 2001 until June 2007. He also served as President of Global Markets and Technology of ABB Ltd. from January 2006 until June 2007, as Chairman and Chief Executive Officer of ABB North America from January 2004 until June 2007, and as President and Chief Executive Officer of ABB Automation Technologies Division from October 2002 to December 2005. Mr. Paliwal is a member of the CEO Business Roundtable in Washington, D.C. and the U.S. India Business CEO Forum.

Theodore Samuels

Mr. Theodore R. Samuels II, is Independent Director of the Company. Mr. Samuels served with Capital Group Companies from 1981 to 2016. He was President of the Capital Guardian Trust Company from 2010 to 2016 and was the Capital Group representative for Focusing Capital on the Long Term from 2014 to 2015. Mr. Samuels was a portfolio manager from 1990 to 2016, and while at Capital Group served on numerous management and investment committees. He also served as a board member of Capital Group Foundation and as Chair of Capital Group Foundation Investment Committee and the Capital International (North America) Proxy Committee. Mr. Samuels served on the Capital Group Finance Committee from 2013-2016 and previously served on the Capital Group Board and the Capital Group Audit Committee. He also serves as Co-chair of Tuft's President's Council, the Harvard West Cost Council and is a member of the Harvard College Fund Executive Committee. Mr. Samuels is a trustee of Children's Hospital Los Angeles, where he served as Co-chair from 2012 to 2015 and is also a trustee of the Pasadena City College Foundation.

Vicki Sato

Dr. Vicki L. Sato, Ph.D., is Independent Director of Bristol-Myers Squibb Company. She has served as a professor of management practice at the Harvard Business School since July 2005. From July 2005 to October 2014 she served as professor of the practice of molecular and cell biology at Harvard University. In 2005, Dr. Sato retired as President of Vertex Pharmaceuticals Incorporated, a global biotechnology company, where she was responsible for research and development, business and corporate development, commercial operations, legal and finance. Dr. Sato also served as Chief Scientific Officer, Senior Vice President of Research and Development and Chair of the Scientific Advisory Board at Vertex before being named President in 2000. She serves as Chairman of Denali Therapeutics, Inc. and VIR Biotechnology, Inc. and a Director of Syros Pharmaceuticals. She is a co-Chair on the Advisory Council for LifeSci NYC. She also serves on the Board of Directors of the Peer Health Exchange, Inc. Dr. Sato will not stand for re-election to the Board of Directors of PerkinElmer at their 2017 annual meeting.

Gerald Storch

Mr. Gerald Leonard Storch is Independent Director of Bristol-Myers Squibb Company. He has served as Chief Executive Officer of Hudson's Bay Company since January 2015, a leading owner and operator of department stores, including Saks Fifth Avenue, Lord & Taylor, Hudson's Bay Department Stores, Home Outfitters, Saks OFF 5th, Kaufhof, Inno and the e-commerce business Gilt. From November 2013 to January 2014 he served as Chairman and Chief Executive Officer of Storch Advisors. He also served as Chairman of Toys"R"Us, Inc. from February 2006 to November 2013 and Chief Executive Officer of Toys"R"Us from February 2006 to May 2013. Prior to joining Toys"R"Us, Mr. Storch served as Vice Chairman of Target Corporation. He joined Target in 1993 as Senior Vice President of Strategy and served in roles of increasing seniority over the next 12 years. Prior to joining Target, Mr. Storch was a partner at McKinsey & Company. He is a director of Fanatics, Inc.